- Conditions
- Multifocal Motor Neuropathy (MMN), MMN
- Interventions
- Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo, IVIg-placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Pomona, California • Rancho Mirage, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 2,822
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Interventions
- ASN008 TG, Placebo TG
- Drug
- Lead sponsor
- Asana BioSciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
- Interventions
- c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cognitive Impairment Associated With Schizophrenia
- Interventions
- MEM 3454, Placebo for MEM 3454
- Drug
- Lead sponsor
- Memory Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 44
- States / cities
- Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more
- Conditions
- Influenza
- Interventions
- Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Miami, Florida • Edison, New Jersey • Austin, Texas
- Conditions
- DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
- Interventions
- AOC 1001, Placebo
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
- Conditions
- Dermatomyositis
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- VX-407, Placebo, Midazolam
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Coronado, California • Pasadena, California + 7 more
- Conditions
- Healthy Volunteers
- Interventions
- Branebrutinib, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Ramantamig, Tocilizumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Goodyear, Arizona • Beverly Hills, California • Irvine, California + 6 more
- Conditions
- Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
- Interventions
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- Roluperidone, risperidone, aripiprazole, olanzapine, Placebo
- Drug
- Lead sponsor
- Minerva Neurosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 13
- States / cities
- Bellflower, California • Culver City, California • Garden Grove, California + 10 more
- Conditions
- Post-laminectomy Pain Syndrome
- Interventions
- Gralise®, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Temporomandibular Disorder
- Interventions
- Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Obesity
- Interventions
- Phosphatidylcholine Deoxycholate, Saline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Placebo, PF-06291874
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Vesatolimod, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 5 more
- Conditions
- Night Eating Syndrome
- Interventions
- Escitalopram, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Durham, North Carolina
- Conditions
- Thrombosis
- Interventions
- BMS-986141, Placebo, Aspirin, Itraconazole
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Cypress, California • Austin, Texas
- Conditions
- Infections, Meningococcal
- Interventions
- Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years to 18 Years
- Enrollment
- 945 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more
- Conditions
- Asthma
- Interventions
- tilrekimig, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- River Forest, Illinois • Hannibal, Missouri • The Bronx, New York + 8 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Hypericum perforatum, Placebo
- Drug · Other
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Kenmore, Washington